Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Fourteen-week Placebo-controlled Dose-response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

NCT00148486 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00148486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00148486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Fourteen-week Placebo-controlled Dose-response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2003
Completion date
Not reported
Enrollment
261
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease